Leerink Partnrs Has Pessimistic View of Certara Q2 Earnings

Certara, Inc. (NASDAQ:CERT - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for Certara in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.06 per share for the quarter, down from their prior forecast of $0.07. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2027 earnings at $0.38 EPS.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 earnings per share.

A number of other equities analysts also recently commented on CERT. KeyCorp lifted their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Morgan Stanley assumed coverage on Certara in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. JMP Securities restated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Finally, Robert W. Baird upped their target price on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Certara currently has an average rating of "Moderate Buy" and an average price target of $15.71.

Certara Stock Performance

Shares of CERT stock traded down $0.33 on Thursday, hitting $11.18. 439,302 shares of the stock traded hands, compared to its average volume of 1,464,271. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. The company has a market capitalization of $1.81 billion, a PE ratio of -558.10 and a beta of 1.43. Certara has a 1-year low of $8.64 and a 1-year high of $16.93. The company's fifty day moving average is $11.46 and its 200 day moving average is $11.86.

Institutional Trading of Certara

Several large investors have recently added to or reduced their stakes in CERT. Versant Capital Management Inc raised its stake in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Certara in the first quarter worth $31,000. Wells Fargo & Company MN increased its stake in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Certara in the first quarter worth $39,000. Finally, Johnson Financial Group Inc. acquired a new position in shares of Certara in the fourth quarter worth $47,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.